ClinicalTrials.gg
CompletedNCT00148798FLEXUpdated Jun 25, 2014Results posted

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

A Phase 3 interventional study of cetuximab + cisplatin + vinorelbine and cisplatin + vinorelbine in Non Small Cell Lung Cancer (NSCLC), sponsored by Merck KGaA, Darmstadt, Germany. Completed at 118 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-25.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,861
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 51
1,861 · median 63
Started
2004
with 7 others
Phase 3
5 of 52
none open now
Registered
15th of 52
by date
Lead sponsor
3 of 52
Merck KGaA, Darmstadt, Germany

Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment of the 51 interventional ones that give a count, is one of 8 that started in 2004, is one of 5 in phase 3, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.

03

Conditions studied

  • Non Small Cell Lung Cancer (NSCLC)

Keywords

  • Cetuximab
  • Non small cell lung cancer
  • Lung cancer
  • Cisplatin/vinorelbine
  • Monoclonal antibody
  • Erbitux
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of or cytologically confirmed NSCLC, stage IIIb with documented malignant pleural effusion or stage IV
  • Immunohistochemical evidence of EGFR expression on tumor tissue
  • Presence of at least 1 bi-dimensionally measurable index lesion, whereby index lesions must not lie in an irradiated area

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFR-targeting therapy
  • Previous chemotherapy for NSCLC
  • Documented or symptomatic
  • Superior vena cava syndrome contra-indicating hydration
  • Previous in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,861 participants (actual)

Study arms

  • Experimental
    Cetuximab plus chemotherapy

    cetuximab + cisplatin + vinorelbine

    Drug: cetuximab + cisplatin + vinorelbine

  • Active comparator
    Chemotherapy alone

    cisplatin + vinorelbine alone

    Drug: cisplatin + vinorelbine

Interventions

  • Drugcetuximab + cisplatin + vinorelbine

    Drug pages: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VinorelbineStudies of VinorelbineVinorelbine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.

  • Drugcisplatin + vinorelbine

    Drug pages: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VinorelbineStudies of VinorelbineVinorelbine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.

06

What researchers measure

Primary outcomes

  1. Overall Survival Time (OS)

    Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

    Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007

Secondary outcomes

  1. Progression-free Survival Time

    Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

    Time frame: Time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007

  2. Best Overall Response Rate

    The best overall response rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007

  3. Disease Control Rate

    The disease control rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007

  4. Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status

    Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.

    Time frame: at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007

  5. Quality of Life Assessment (EORTC QLQ-C30) Social Functioning

    Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.

    Time frame: at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007

  6. A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations

    Population PK analysis was conducted using non-linear mixed effects modeling (NONMEM) software, integrating the PK data from this study and the Phase II study EMR 62 202-011.

    Time frame: Week 1, Day 1: baseline and end of infusion; Week 7, Day 43: within 12 h after cetuximab administration.

  7. Safety - Number of Patients Experiencing Any Adverse Event

    Please refer to Adverse Events section for further details

    Time frame: time from first dose up to 30 after last dose of study treatment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007

07

Results

Posted Oct 4, 2011

Participant flow

First/last subject (informed consent): October 2004/January 2006. Clinical data cut-off: 18 July 2007. Last subject completed 16 May 2012. Subjects randomized at 155 centers; Asia/Australia: 21; Europe: 120; South America: 14.

Participant flow — Overall Study
MilestoneCetuximab Plus ChemotherapyChemotherapy Alone
Started557568
Completed557568
Not completed00

Outcome measures

PrimaryOverall Survival Time (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

Time frame:
Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Reported as:
Median · months
Overall Survival Time (OS)
monthsCetuximab Plus ChemotherapyChemotherapy Alone
Overall Survival Time (OS)11.3 (9.4 to 12.4)10.1 (9.1 to 10.9)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Stratified Log Rank · p = 0.0441
SecondaryProgression-free Survival Time

Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

Time frame:
Time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Reported as:
Median · months
Progression-free Survival Time
monthsCetuximab Plus ChemotherapyChemotherapy Alone
Progression-free Survival Time4.8 (4.2 to 5.3)4.8 (4.4 to 5.4)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Stratified Log Rank · p = 0.3869
SecondaryBest Overall Response Rate

The best overall response rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Reported as:
Number · percentage of participants
Best Overall Response Rate
percentage of participantsCetuximab Plus ChemotherapyChemotherapy Alone
Best Overall Response Rate36.4 (32.4 to 40.6)29.2 (25.5 to 33.2)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Cochran-Mantel-Haenszel · p = 0.0101
SecondaryDisease Control Rate

The disease control rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Reported as:
Number · percentage of participants
Disease Control Rate
percentage of participantsCetuximab Plus ChemotherapyChemotherapy Alone
Disease Control Rate72.5 (68.6 to 76.2)71.5 (67.6 to 75.2)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Cochran-Mantel-Haenszel · p = 0.6801
SecondaryQuality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status

Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.

Time frame:
at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Reported as:
Least squares mean · scores on a scale
Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
scores on a scaleCetuximab Plus ChemotherapyChemotherapy Alone
At baseline45.72 ± 2.16446.36 ± 2.138
At cycle 348.33 ± 2.32551.55 ± 2.464
At month 654.71 ± 2.72952.92 ± 2.787
SecondaryQuality of Life Assessment (EORTC QLQ-C30) Social Functioning

Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.

Time frame:
at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Reported as:
Least squares mean · scores on a scale
Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
scores on a scaleCetuximab Plus ChemotherapyChemotherapy Alone
At baseline66.17 ± 2.83664.73 ± 2.825
At cycle 358.05 ± 2.99567.13 ± 3.138
At month 667.36 ± 3.44966.47 ± 3.515
SecondaryA Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations

Population PK analysis was conducted using non-linear mixed effects modeling (NONMEM) software, integrating the PK data from this study and the Phase II study EMR 62 202-011.

Time frame:
Week 1, Day 1: baseline and end of infusion; Week 7, Day 43: within 12 h after cetuximab administration.
Reported as:
Mean · ug/mL
A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations
ug/mLCetuximab Concentration at End of Infusion Week 1Cetuximab Concentration Before Infusion Week 7
A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations223.1 ± 64.651.5 ± 33.1
SecondarySafety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for further details

Time frame:
time from first dose up to 30 after last dose of study treatment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Reported as:
Number · participants
Safety - Number of Patients Experiencing Any Adverse Event
participantsCetuximab Plus ChemotherapyChemotherapy Alone
Safety - Number of Patients Experiencing Any Adverse Event545549

Adverse events

Collected over Time from first dose up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab Plus Chemotherapy—325/548 (59.3%)532/548 (97.1%)
Chemotherapy Alone—244/562 (43.4%)537/562 (95.6%)
Most frequent serious events
Showing 10 of 248
Most frequent serious events
EventCetuximab Plus ChemotherapyChemotherapy Alone
Febrile neutropeniaBlood and lymphatic system disorders96/54867/562
NeutropeniaBlood and lymphatic system disorders47/54833/562
General physical health deteriorationGeneral disorders22/5484/562
Pulmonary embolismRespiratory, thoracic and mediastinal disorders20/54813/562
PneumoniaInfections and infestations19/54813/562
DyspnoeaRespiratory, thoracic and mediastinal disorders18/54813/562
VomitingGastrointestinal disorders16/54814/562
PyrexiaGeneral disorders16/5486/562
LeukopeniaBlood and lymphatic system disorders15/5488/562
Respiratory failureRespiratory, thoracic and mediastinal disorders14/5489/562
Most frequent other events
Showing 10 of 60
Most frequent other events
EventCetuximab Plus ChemotherapyChemotherapy Alone
NeutropeniaBlood and lymphatic system disorders302/548324/562
NauseaGastrointestinal disorders291/548303/562
AnaemiaBlood and lymphatic system disorders226/548264/562
RashSkin and subcutaneous tissue disorders249/54817/562
VomitingGastrointestinal disorders214/548225/562
AnorexiaMetabolism and nutrition disorders208/548202/562
ConstipationGastrointestinal disorders204/548189/562
FatigueGeneral disorders202/548181/562
LeukopeniaBlood and lymphatic system disorders176/548155/562
DiarrhoeaGastrointestinal disorders126/548103/562

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cetuximab Plus ChemotherapyChemotherapy AloneTotal
Median59 (18 to 78)60 (20 to 83)59 (18 to 83)
Age, Customized
Age, Customized(participants)Cetuximab Plus ChemotherapyChemotherapy AloneTotal
<18 years000
Between 18 and 65 years385389774
>=65 years172179351
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab Plus ChemotherapyChemotherapy AloneTotal
Female172163335
Male385405790
Region of Enrollment
Region of Enrollment(participants)Cetuximab Plus ChemotherapyChemotherapy AloneTotal
Australia202343
Hong Kong224
Singapore5510
Korea, Republic of282654
Taiwan212243
Austria9716
Belgium31013
Bulgaria121224
Czech Republic121729
France252550
Germany9188179
Hungary212344
Ireland347
Netherlands101020
Poland5950109
Portugal303
Russian Federation231639
Slovakia81220
Spain161329
Sweden639
Switzerland10616
Turkey123
United Kingdom232144
Ukraine5671127
Chile101626
Italy182341
Argentina527
Mexico9817
Brazil485199
08

Study locations

118 sites
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Cordoba, Argentina
  • Research Site
    Adelaide, Australia
  • Research Site
    Melbourne, Australia
  • Research Site
    Randwick, Australia
  • Research Site
    Sydney, Australia
  • Research Site
    Wodonga, Australia
  • Research Site
    Wien, Austria
  • Research Site
    Bruxelles, Belgium
  • Research Site
    Charleroi, Belgium
  • Research Site
    Liège, Belgium
  • Research Site
    Porto Alegre, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Stara Zagora, Bulgaria
  • Research Site
    Veliko Tarnovo, Bulgaria
  • Research Site
    Antofagasta, Chile
  • Research Site
    Santiago de Chile, Chile
  • Research Site
    Brno, Czech Republic
  • Research Site
    Ostrava, Czech Republic
  • Research Site
    Pilsen, Czech Republic
  • Research Site
    Praha, Czech Republic
  • Research Site
    Brest, France
  • Research Site
    Caen, France
  • Research Site
    Grenoble, France
  • Research Site
    Marseille, France
  • Research Site
    Paris, France
  • Research Site
    Poitiers, France
  • Research Site
    Rennes, France
  • Research Site
    Rouen, France
  • Research Site
    Strasbourg, France
  • Research Site
    Augsburg, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Gauting, Germany
  • Research Site
    Großhansdorf, Germany
  • Research Site
    Göttingen, Germany
  • Research Site
    Halle-Dölau, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Köln, Germany
  • Research Site
    Löwenstein, Germany
  • Research Site
    Magdeburg, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    München, Germany
  • Research Site
    Stralsund, Germany
  • Research Site
    Wuppertal, Germany
  • Research Site
    Honh Kong, Hong Kong
  • Research Site
    Budapest, Hungary
  • Research Site
    Nyiregyháza, Hungary
  • Research Site
    Szombathely, Hungary
  • Research Site
    Székesfehérvár, Hungary
  • Research Site
    Torokbalint, Hungary
  • Research Site
    Zalegerzeg-Pózva, Hungary
  • Research Site
    Dublin, Ireland
  • Research Site
    Bologna, Italy
  • Research Site
    Carpi, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Rome, Italy
  • Research Site
    Rozzano-Milano, Italy
  • Research Site
    Treviglio, Italy
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Mexico-City, Mexico
  • Research Site
    Monterrey, Mexico
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Nieuwegeln, Netherlands
  • Research Site
    Zwolle, Netherlands
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Olsztyn, Poland
  • Research Site
    Otwock, Poland
  • Research Site
    Posnan, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Wroclaw, Poland
  • Research Site
    Moscow, Russian Federation
  • Research Site
    St. Petersburg, Russian Federation
  • Research Site
    Singapore, Singapore
  • Research Site
    Banska Bystrica, Slovakia
  • Research Site
    Bratislava, Slovakia
  • Research Site
    Nitra-Zobor, Slovakia
  • Research Site
    Poprad, Slovakia
  • Research Site
    Barakaldo (Bilbao), Spain
  • Research Site
    Barcelona, Spain
  • Research Site
    Elche Alicante, Spain
  • Research Site
    Granollers, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Pamplona, Spain
  • Research Site
    Pontevedra, Spain
  • Research Site
    San Sebastian, Spain
  • Research Site
    Santander, Spain
  • Research Site
    Terrassa, Spain
  • Research Site
    Valencia, Spain
  • Research Site
    Stockholm, Sweden
  • Research Site
    Uppsala, Sweden
  • Research Site
    Bern, Switzerland
  • Research Site
    Thun, Switzerland
  • Research Site
    Zürich, Switzerland
  • Research Site
    Taipei, Tao Yuan County, Taiwan
  • Research Site
    Taipei, Taiwan

Showing the first 100 of 118 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9. PubMed 19410716 ↗
  • Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, Heeger S, Goddemeier T, O'Byrne KJ, Gatzemeier U. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer. 2012 Aug;77(2):376-82. doi: 10.1016/j.lungcan.2012.03.010. Epub 2012 Apr 11. PubMed 22498112 ↗
  • Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012 Jan;13(1):33-42. doi: 10.1016/S1470-2045(11)70318-7. Epub 2011 Nov 4. PubMed 22056021 ↗
  • O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011 Aug;12(8):795-805. doi: 10.1016/S1470-2045(11)70189-9. Epub 2011 Jul 22. PubMed 21782507 ↗
  • Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ, Pirker R. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011 Jan;12(1):30-7. doi: 10.1016/S1470-2045(10)70278-3. Epub 2010 Dec 17. PubMed 21169060 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Jul 2007 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2005
First posted
Sep 8, 2005
Start
Oct 2004
Primary completionActual
Jul 2007
CompletionActual
May 2012
Results first posted
Oct 4, 2011
Last update
Jun 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00148798
Responsible party
Sponsor
First posted
Sep 8, 2005
Start date
Oct 2004
Primary completion
Jul 2007
Completion
May 2012
Results posted
Oct 4, 2011
Last update
Jun 25, 2014

Study contacts

Robert Pirker, Professor
principal investigator · Universitätsklinik für Innere Medizin I, Wien

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Cisplatin · Vinorelbine

Start the discussion